Clinical Trial

Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CLEVELAND, July 03, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has raised $25 million…

12 months ago

Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.

YUSIMRY™ (adalimumab-aqvh) product image YUSIMRY™ (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for…

12 months ago

Zymeworks Announces Participation in Upcoming Investor Conference

VANCOUVER, British Columbia, July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional…

12 months ago

NorthX Biologics, a leading Nordic development and manufacturing organisation announces acquisition of a biologics manufacturing unit from Valneva

MATFORS, Sweden, July 03, 2023 (GLOBE NEWSWIRE) -- NorthX Biologics (‘NorthX’), a leading Nordic development and manufacturing organisation with a…

12 months ago

Fortrea Launches as Leading, Global Contract Research Organization Positioned to Bring Life-Changing Therapies to Patients Faster

Company completes spin-off from Labcorp and begins trading on Nasdaq under ticker “FTRE” Independent company positioned to capitalize on growth…

12 months ago

Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space

Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab…

12 months ago

Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy

Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface…

1 year ago

Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Madrigal expects to complete full submission of the New Drug Application in July 2023CONSHOHOCKEN, Pa., June 30, 2023 (GLOBE NEWSWIRE)…

1 year ago

Baudax Bio Acquires TeraImmune, Inc.

TeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the…

1 year ago